I used lovastatin about 10 years ago and had what I termed a miraculous improvement in mobility. It lasted for several months; when my condition began to deteriorate, I went off lovastatin, but just last week started it again, hoping of course for repeated improvement.
Feb. 10: Since my message 3 months ago (see above), I have continued lovastatin and I do see a difference in walking though not in balance. I can't say whether lovastatin is responsible because I am diligently trying new and more exercise. Furthermore, the newest United Leukodystrophy Foundation newsletter includes the following report:
Marc Engelen, PhD (Academic Medical Center, Amsterdam) performed a clinical trial to determine whether Lovastatin was effective in lowering C26:0 levels in AMN patients. Using a placebo-controlled, randomized, crossover design, he treated 14 patients with Lovastatin or placebo for 6 months. LDL-cholesterol decreased 60% on Lovatatin as expected and plasma C26:0 decreased by 30%, but lymphocytes showed no change. The C26:0 content of plasma LDL-cholesterol also showed no change when normalized to LDL concentration, which suggests that the plasma
C26:0 reduction on Lovastatin was a secondary effect of decreased LDL. Since lymphocytes did not exhibit a reduction in C26:0 on Lovistatin, the drug probably has no effect on tissue levels of this fatty acid. He concludes that Lovastatin
has no biochemical benefit for AMN patients.